Susceptibility of CTCL-derived tumor cells to VSV is independent of IFN-α treatment
| Patients . | −IFN-α . | +IFN-α . | ||||||
|---|---|---|---|---|---|---|---|---|
| Total cells . | Infected . | % Infected . | MxA . | Total cells . | Infected . | % Infected . | MxA . | |
| R (nonclonal) | 273 | 97 | 36 | ± | 287 | 11 | 4 | +++ |
| R (clonal Vβ6.7+) | 102 | 45 | 44 | − | 115 | 49 | 43 | − |
| X(nonclonal) | 255 | 86 | 34 | ± | 216 | 25 | 12 | ++ |
| X (clonal Vβ5a+) | 95 | 52 | 44 | − | 103 | 44 | 43 | − |
| P (nonclonal) | 236 | 91 | 39 | ± | 267 | 5 | 2 | +++ |
| P (clonal Vβ3.1+) | 100 | 39 | 39 | − | 85 | 31 | 36 | − |
| Patients . | −IFN-α . | +IFN-α . | ||||||
|---|---|---|---|---|---|---|---|---|
| Total cells . | Infected . | % Infected . | MxA . | Total cells . | Infected . | % Infected . | MxA . | |
| R (nonclonal) | 273 | 97 | 36 | ± | 287 | 11 | 4 | +++ |
| R (clonal Vβ6.7+) | 102 | 45 | 44 | − | 115 | 49 | 43 | − |
| X(nonclonal) | 255 | 86 | 34 | ± | 216 | 25 | 12 | ++ |
| X (clonal Vβ5a+) | 95 | 52 | 44 | − | 103 | 44 | 43 | − |
| P (nonclonal) | 236 | 91 | 39 | ± | 267 | 5 | 2 | +++ |
| P (clonal Vβ3.1+) | 100 | 39 | 39 | − | 85 | 31 | 36 | − |
Immunofluorescence analysis of MxA: +++, strong expression in >95% of cells; ++, clearly detectable expression in >95% of cells; ±, expression in 1% to 3% of cells; −, no expression detectable.